Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

13.03
-0.1500-1.14%
Pre-market: 13.280.2500+1.92%08:43 EDT
Volume:840.28K
Turnover:11.05M
Market Cap:792.64M
PE:-7.11
High:13.40
Open:13.23
Low:13.02
Close:13.18
52wk High:35.34
52wk Low:12.12
Shares:60.83M
Float Shares:41.68M
Volume Ratio:0.72
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8336
EPS(LYR):-1.8336
ROE:-11.48%
ROA:-9.55%
PB:0.83
PE(LYR):-7.11

Loading ...

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of Janx011

THOMSON REUTERS
·
Feb 17

Janux Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer William Go

Reuters
·
Feb 05

Janux Therapeutics Names William Go as Chief Medical Officer

Reuters
·
Jan 26

Janux Therapeutics Appoints William Go, M.d., Ph.d., as Chief Medical Officer

THOMSON REUTERS
·
Jan 26

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Benzinga
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel

Reuters
·
Jan 23

Janux Therapeutics: Bristol Myers Collaboration Validates Tumor-Activated Platform and Enhances Risk–Reward Profile

TIPRANKS
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital

Reuters
·
Jan 22

Janux Therapeutics Shares Jump 14.5% Premarket on Global License Deal With Bristol Myers for Cancer Drug Development

THOMSON REUTERS
·
Jan 22

BRIEF-Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy

Reuters
·
Jan 22

Janux Therapeutics Inc - Co Also Entitled to Tiered Royalties on Global Sales

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement With Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Inc - as Part of Collaboration, Co Will Complete Preclinical Development up to Ind Submission

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Inc - as Part of Collaboration, Bristol Will Hold Ind & Be Responsible for Subsequent Development & Global Commercialization

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Inc - to Receive up to $50 Mln Upfront, $800 Mln in Milestones

THOMSON REUTERS
·
Jan 22

Janux Therapeutics: Under Terms, Co Is Eligible to Receive Development, Regulatory & Commercial Milestones up to About $800 Mln in Aggregate

THOMSON REUTERS
·
Jan 22

Janux Therapeutics Cut to Hold From Buy by Clear Street

Dow Jones
·
Jan 20

Janux Therapeutics downgraded to Hold from Buy at Clear Street

TIPRANKS
·
Jan 20

Janux Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 17

Janux Therapeutics price target lowered to $30 from $42 at Piper Sandler

TIPRANKS
·
Jan 16